# The infection–microbiome–immunity axis in bladder cancer: mechanistic insights and therapeutic perspectives

**Authors:** Shen Pan, Wanlin Cui, Jiaman Lin, Zhujun Wang, Zhenhua Li, Bitian Liu

PMC · DOI: 10.3389/fimmu.2025.1716230 · Frontiers in Immunology · 2026-01-12

## TL;DR

This review explores how infections, gut and urinary microbiome imbalances, and immune system aging contribute to bladder cancer and suggests new treatment strategies.

## Contribution

The paper provides a conceptual framework linking infection, microbiome dysbiosis, and immune dysfunction in bladder cancer.

## Key findings

- Microbial dysbiosis and chronic infections drive bladder cancer through inflammation and immune disruption.
- Immunosenescence worsens microbial persistence and weakens antitumor immunity in bladder cancer.
- Microbiome-targeted and immunomodulatory therapies show promise for restoring immune-microbial balance.

## Abstract

Bladder cancer (BC) represents a paradigm of infection-associated malignancy in which microbial dysbiosis, immune aging, and tumor microenvironmental remodeling converge to shape disease progression. Increasing evidence highlights the dual role of the urinary and gut microbiota in modulating bladder carcinogenesis through infection-driven inflammation and immune dysfunction. Chronic exposure to uropathogens and microbial imbalance disrupts epithelial integrity, promotes extracellular matrix degradation, and reprograms local immune signaling, collectively fostering a tumor-permissive niche. Concurrently, immunosenescence exacerbates microbial persistence and impairs antitumor immunity, reinforcing a pathogenic feedback loop between infection and immune decline. This review integrates current insights from microbiome research, tumor immunology, and microbial pathogenesis to delineate the mechanistic continuum linking infection, dysbiosis, and immune remodeling in BC. Finally, we discuss emerging microbiome-targeted and immunomodulatory strategies aimed at restoring microbial–immune equilibrium and improving therapeutic efficacy. Together, these perspectives provide a refined conceptual framework for understanding infection-driven oncogenesis and guiding precision interventions in BC.

## Linked entities

- **Diseases:** bladder cancer (MONDO:0004986)

## Full-text entities

- **Diseases:** malignancy (MESH:D009369), BC (MESH:D001749), infection (MESH:D007239), bladder carcinogenesis (MESH:D063646), inflammation (MESH:D007249), dysbiosis (MESH:D064806), immune dysfunction (MESH:D007154)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12832868/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12832868/full.md

## References

183 references — full list in the complete paper: https://tomesphere.com/paper/PMC12832868/full.md

---
Source: https://tomesphere.com/paper/PMC12832868